You are here

Preclinical Studies of PG70 LEAPS Peptide Vaccines for Rheumatoid Arthritis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AR063504-01A1
Agency Tracking Number: R43AR063504
Amount: $224,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAMS
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
8229 BOONE BLVD SUITE 802
VIENNA, VA 22182-2634
United States
DUNS: 102560141
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DANIEL ZIMMERMAN
 (703) 506-9469
 dzimmerman@cel-sci.com
Business Contact
 PATRICIA PRICHEP
Phone: (703) 506-9460
Email: pprichep@cel-sci.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Currently, FDA-licensed pharmaceuticals used to treat rheumatoid arthritis (RA) focus largely on alleviation of symptoms, either through pain management, general immunosuppression, or by antagonizing cytokines such as TNF-?. Despite recent advances in biologic therapies, these treatments do not address the underlying autoimmune condition. Ligand epitope antigen presentation system (L.E.A.P.S. ) conjugates are a peptide vaccine platform designed to modulate the immune response in an antigen-specific manner. LEAPS are composed of two peptide components, an immune cell binding ligand (ICBL) and a peptide (epitope) implicated in an infectious or autoimmune disease. The ICBLs include peptide J from human -2 microglobulin, with Th1-polarizing activity, and peptide derG (or G) from human MHC class II chain with Th2 polarizing activity. In mice with collagen-induced arthritis (CIA), a Th17-mediated disease, a J-collagen peptide conjugate reduced disease severity by suppressing

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government